219 related articles for article (PubMed ID: 24195711)
1. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
Dawson LA
Expert Opin Drug Discov; 2013 Dec; 8(12):1529-39. PubMed ID: 24195711
[TBL] [Abstract][Full Text] [Related]
2. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
3. Vilazodone: a novel antidepressant.
Choi E; Zmarlicka M; Ehret MJ
Am J Health Syst Pharm; 2012 Sep; 69(18):1551-7. PubMed ID: 22935937
[TBL] [Abstract][Full Text] [Related]
4. Vilazodone: in major depressive disorder.
Frampton JE
CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
[TBL] [Abstract][Full Text] [Related]
5. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
Guay DR
Consult Pharm; 2012 Dec; 27(12):857-67. PubMed ID: 23229074
[TBL] [Abstract][Full Text] [Related]
6. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
Khan A
Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
[TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.
de Paulis T
IDrugs; 2007 Mar; 10(3):193-201. PubMed ID: 17351874
[TBL] [Abstract][Full Text] [Related]
8. Vilazodone (Viibryd)--a new antidepressant.
Med Lett Drugs Ther; 2011 Jul; 53(1368):53-4. PubMed ID: 21738107
[TBL] [Abstract][Full Text] [Related]
9. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor.
Stahl SM
CNS Spectr; 2014 Apr; 19(2):105-9. PubMed ID: 24673885
[TBL] [Abstract][Full Text] [Related]
11. Vilazodone for the treatment of major depressive disorder.
Iranikhah M; Wensel TM; Thomason AR
Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
[TBL] [Abstract][Full Text] [Related]
12. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
[TBL] [Abstract][Full Text] [Related]
13. Vilazodone for the treatment of depression.
Lindsey WT
Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
[TBL] [Abstract][Full Text] [Related]
14. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
Jain R; Chen D; Edwards J; Mathews M
Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
[TBL] [Abstract][Full Text] [Related]
15. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
17. Vilazodone: another novel atypical antidepressant drug.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Mar; 49(3):19-22. PubMed ID: 21323263
[TBL] [Abstract][Full Text] [Related]
18. Vilazodone approved for major depression.
Traynor K
Am J Health Syst Pharm; 2011 Mar; 68(5):366. PubMed ID: 21330672
[No Abstract] [Full Text] [Related]
19. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
20. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
Robinson DS; Kajdasz DK; Gallipoli S; Whalen H; Wamil A; Reed CR
J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
